Literature DB >> 9692536

Generics: what's in a name?

L G Keith1, J J Oleszczuk, C S Stika, S Stine.   

Abstract

Historically, the most common intervention performed by physicians has been the writing of a prescription. Often the prescription was a combination of active agents and an inactive base. This art is no longer practiced in the United States. Currently, most prescriptions are written for specific "drugs." As the prescription is being written, the physician must decide to administer a brand-name or a generic equivalent. Generics are a class of medications prescribed for reasons of economy, and the physician and the patient expect that the therapeutic effect will be exactly the same as for the brand-name. Bioequivalence of specific agents can be assessed using the FDA's Orange Book. In addition to bioequivalence, many other scientific, ethical, and economic issues should be considered before a decision is made. Prescribing vigilance is necessary, because in many instances available information is often controlling or insufficient to support rational decisions. Brand-names, rather than generics, should be selected when the therapeutic index is narrow or if the likelihood of generic switching is high. The paper will discuss all aspects of the subject.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9692536

Source DB:  PubMed          Journal:  Int J Fertil Womens Med        ISSN: 1534-892X


  6 in total

Review 1.  Generic antiarrhythmic drugs: what constitutes equivalency.

Authors:  D G Benditt
Journal:  J Interv Card Electrophysiol       Date:  1999-07       Impact factor: 1.900

Review 2.  [Original brands and generic preparations].

Authors:  K U Petersen
Journal:  Med Klin (Munich)       Date:  2000-01-15

Review 3.  Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.

Authors:  Aaron S Kesselheim; Alexander S Misono; Joy L Lee; Margaret R Stedman; M Alan Brookhart; Niteesh K Choudhry; William H Shrank
Journal:  JAMA       Date:  2008-12-03       Impact factor: 56.272

4.  Efficacy and Safety of Dorocontin(®) versus Sustac(®) in the Treatment of Stable Angina Pectoris: A Randomized, Double-Blind Comparative Trial.

Authors:  Yunes Panahi; Bahram Pishgoo; Yahya Dadjou; Manouchehr Mehdirad; Sara Saffar Soflaei; Amirhossein Sahebkar
Journal:  Sci Pharm       Date:  2014-08-16

5.  Investigation of the efficacy of generic and brand-name tiotropium bromide in the management of chronic obstructive pulmonary disease: A randomized comparative trial.

Authors:  Yunes Panahi; Mostafa Ghanei; Mohammad Behzadi; Maryam Salehi; Sara Saffar Soflaei; Amirhossein Sahebkar
Journal:  Saudi Pharm J       Date:  2015-01-12       Impact factor: 4.330

6.  Investigation of the efficacy of generic and brand-name salmeterol/fluticasone combination in the management of asthma: a randomized comparative trial.

Authors:  Yunes Panahi; Mostafa Ghanei; Hooshyar Maghsoudi; Sara Saffar Soflaei; Amirhossein Sahebkar
Journal:  Acta Biomed       Date:  2018-06-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.